Abstract

Human epidermal growth factor receptor -2 (HER-2) - positive breast cancer is a kind of tumor with strong invasiveness and poor prognosis. Trastuzumab anti Her-2 targeted drugs has changed the prognosis of Her-2 positive breast cancer. In addition to the drug trastuzumab, a series of anti-Her-2 targeted drugs have been used in clinical research and treatment, including small molecule tyrosine kinase inhibitor (lapatinib and neratinib), anti-Her-2 molecular heterodimerization drug (pertuzumab), and cell toxicity of trastuzumab conjugated drug (T-DM1). This article is to review the treatment of HER-2 positive early breast cancer. Key words: Human epidermal growth factor receptor-2; Breast cancer; Trastuzumab; Pertuzumab; Lapatinib

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.